Shwetal Mehta, PhD, emphasizes her institution’s patient-focused and scientifically rigorous philosophy when developing new therapies in brain cancer.
Shwetal Mehta, PhD
Advertisement
Articles by Shwetal Mehta, PhD
Shwetal Mehta, PhD, describes efforts regarding the development of protein degraders and antibody-drug conjugates in the neuro-oncology field.
Liquid biopsy tests may help determine the extent of activity among patients who receive a novel fourth-generation EGFR inhibitor for brain cancer.
Shwetal Mehta, PhD, highlights novel brain cancer drug development procedures in the clinical lab and pre-clinical arms of the Ivy Brain Tumor Center.
Advertisement
Latest Updated Articles
Evaluating a CNS-Penetrant EGFR Inhibitor in Brain CancerJanuary 16th 2025
- Performing Timely Testing in Novel Brain Cancer Therapy Development
January 15th 2025
Advertisement
Advertisement
Trending on CancerNetwork
1
124 Real-World Progression-Free Survival 2 and Tumor Response of CDK4/6is + Aromatase Inhibitor in Patients With HR+/HER2– Metastatic Breast Cancer
2
FDA Clears AI Stratification Tool in HR+/HER2– Invasive Breast Cancer
3
FDA Approves Zenocutuzumab in NRG1+ Cholangiocarcinoma Post Systemic Therapy
4
123 Real-World Patient and Caregiver Experiences With Breast Cancer (BC) Risk of Recurrence (ROR) in the US: Results of an Online Survey and Social Media Analysis
5